Opioids trigger breast cancer metastasis through E-Cadherin downregulation and STAT3 activation promoting epithelial-mesenchymal transition

Tripolt, Sabrina; Knab, Vanessa M.; Neubauer, Heidi A.; Elmer, Dominik P.; Aberger, Fritz; Moriggl, Richard; Fux, Daniela

doi:10.1101/443663

Cited by 2 publications

(2 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,7 The role of ORPD1 is less clear, with antitumour associations shown in TNBC specifically, 45 but also protumour associations in breast cancer generally. 46,47 A variety of evidence links OPRM1 expression to protumour outcomes in cancer. 28,39,40 We found in TNBC that differential expression of these receptor genes is consistent with a net protective effect of opioid agonism: protumour receptors are either not expressed (OPRM1) or downregulated (TLR4), while antitumour receptors (OGFR, OPRK1, OPRD1) are upregulated.…”

Section: Discussionmentioning

confidence: 99%

Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer

Montagna

Gupta

Hannum

et al. 2021

British Journal of Anaesthesia

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer

Montagna

Gupta

Hannum

et al. 2021

British Journal of Anaesthesia

View full text Add to dashboard Cite

“…As for the other opioid receptor targets, the OGFR has shown inhibitory effects in tumor growth ( 3 ), while the role of DOR and KOR are even more controversial with data showing both activating ( 24 ) and suppressing effects ( 25 ) which can be explained by a different profile of receptor expression ( 16 ). In addition, activated opioid receptors trigger several intracellular responses that are responsible for their divergent pharmacological outcomes.…”

Section: Introductionmentioning

confidence: 99%

Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study

et al. 2022

View full text Add to dashboard Cite

BackgroundThere is growing interest in the possible effect of perioperative anesthetic management on the growth and spread of cancer. The impact of perioperative use of opioids on cancer recurrence remains controversial and an assessment cannot yet be established based on current publications. This study aimed to assess the differential expression of opioid receptors between healthy and tumor tissues in patients with stage II and III colorectal cancer undergoing elective surgery by immunohistochemistry (IHC).MethodsPropensity–score matched case–control study nested in a retrospective cohort of patients with stage II or III colorectal. The primary endpoint was the difference in µ–opioid receptor (MOR) expression measured by IHC between tumor and healthy tissue in subject with or without recurrence. Secondary endpoints were to evaluate the differences in Opioid Growth Factor Receptor (OGFR), cyclic adenosine monophosphate (cAMP) production and protein kinase A (PKA) in the matched sample and from a from samples of colorectal cancer stored in the Cancer Genome Atlas (TCGA) and Genotype Tissue Expression Project (GTEx).ResultsThere was a significant difference in MOR receptor (median 3 [intequartile range IQR: 1–3] and 0 [IQR: 0–2], P<0.001) and OGFR receptor (median 6 [IQR: 5–6] and 2 [IQR: 1–2], P<0.001) in tumor and control tissue respectively. However, there were no significant differences in cAMP nor PKA expression between both types of tissues and in expression in any of the analyzed variables by recurrence status. The MOR and OGFR expression data from TCGA database were similar to our sample size data with lower expression of MOR and higher expression of OGFR in tumoural samples with a skewed distribution for MOR expression in tumor tissue both in patients with and without recurrence.ConclusionIn patients with stage II and III colorectal cancer, overall expression of MOR and OGFR was significantly increased but was not different between previously matched patients with or without recurrence. No differences were found in the analyzed metabolic pathway of cAMP–PKA: These results were confirmed by an in silico analysis of samples from the TCGA–GTEx database.

show abstract

Opioids trigger breast cancer metastasis through E-Cadherin downregulation and STAT3 activation promoting epithelial-mesenchymal transition

Cited by 2 publications

References 61 publications

Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer

Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer

Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study

Contact Info

Product

Resources

About